Agentix Corp. in brief
Agentix Corp. is a listed company in the Biotechnology industry, based in Dana Point, California, USA. Its last known market value was $31 M (January 2022); there is no current figure.
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About Agentix Corp.
The Company was incorporated in the State of Nevada on April 18, 2013 and has established a fiscal year end of March 31. Effective June 17, 2019, we changed our name from FairWind Energy, Inc. to Agentix Corp. and to better reflect the new focus of our business. We are a clinical development stage corporation with a focus on pharmaceutical treatments in the metabolic disease space and have not yet generated or realized meaningful revenues from our business.
Until recently, our business plan focused on the design, engineering and manufacturing of composite products, specifically the supply products to the oil and gas industry. However, on May 28, 2020, entered into a Share Exchange Agreement with GSL Healthcare, Inc., a Nevada corporation, and the holders of common stock of GSL Healthcare, which consisted of two stockholders. The closing date occurred on June 1, 2020.
From the company's annual report filed with the US SEC: read the report
Agentix Corp. timeline
- 2014
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 2019
- ✎Renamed Agentix Corp.Formerly FairWind Energy Inc..
Events of Agentix Corp. from SEC EDGAR. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
Not enough history yet.
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Mar 2026 | — | — | $-0M | $-0M | — |
| Mar 2025 | — | — | $-1M | $-1M | — |
| Mar 2024 | — | — | $-1M | $-1M | — |
| Mar 2023 | — | — | $-1M | $-1M | — |
| Mar 2022 | $0M | — | $-3M | $-3M | — |
| Aug 2019 | — | — | $-0M | $-0M | — |
| Aug 2018 | — | — | $-0M | $-43M | — |
| Aug 2017 | — | — | $-0M | $-0M | — |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Mar 2026 | $-0M | — | — | $-0.01 | — |
| Mar 2025 | $-0M | — | — | $-0.01 | — |
| Mar 2024 | $-0M | — | — | $-0.01 | — |
| Mar 2023 | $-0M | — | — | — | — |
| Mar 2022 | $-0M | — | — | $-0.04 | — |
| Aug 2019 | $-0M | — | — | $-6.45 | — |
| Aug 2018 | $-0M | — | — | $-3875.40 | — |
| Aug 2017 | $-0M | — | — | $-0.06 | — |
Quarterly results
Latest quarter to Sep 2026: revenue —, net income $-0M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.
SEC filings
- Nov 6, 202610-QQuarterly report · period to Sep 2026
- Aug 10, 202610-QQuarterly report · period to Jun 2026
- Jul 1, 202610-KAnnual report · period to Mar 2026
- Feb 17, 202610-QQuarterly report · period to Dec 2025
- Nov 20, 202510-QQuarterly report · period to Sep 2025
- Aug 22, 202510-QQuarterly report · period to Jun 2025
- Jul 16, 202510-KAnnual report · period to Mar 2025
- Feb 18, 202510-QQuarterly report · period to Dec 2024
- Nov 18, 202410-QQuarterly report · period to Sep 2024
- Sep 25, 202410-QQuarterly report · period to Jun 2024
- Aug 30, 202410-KAnnual report · period to Mar 2024
- Feb 14, 202410-QQuarterly report · period to Dec 2023
Official filings of Agentix Corp. with the US Securities and Exchange Commission.
Annual results
- Revenue
- —
- Operating income
- $-0 M
- Net income
- $-0 M
For year ending March-2026 · source: SEC filing
Balance sheet
- Total assets
- $0 M
- Total liabilities
- $4 M
- Total equity
- $-4 M
As of March-2026
Insider trading at Agentix Corp.#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | Grays Peak Ventures LLC10% owner | Buy | +767,000 | — | — | 2.19 M | Form 4 |
| filed | Michael WinterhalterPres, Treasurer & Secretary, Director | Buy | +150,000 | — | — | 150,000 | Form 4 |
| filed | Grays Peak Ventures LLC10% owner | Other | +1.41 M | $20.44 | $28.8 M | 1.42 M | Form 4 |
| filed | Michael WinterhalterPres, Treasurer & Secretary, Director | Sell | -10,015 | $20.44 | $205 K | 0 | Form 4 |
| filed | Grays Peak Ventures LLC10% owner | Buy | +9,358 | $20.44 | — | 14,070 | Form 4 |
| filed | Michael Winterhalter10% owner | Sell | -8,433 | $20.44 | $172 K | 10,035 | Form 4 |
| filed | Scott B. StevensPresident, Director, 10% owner | Buyindirect | +9,358 | $20.44 | $191 K | 14,070 | Form 4 |
| filed | Scott ThomasDirector | Grant or award | +5,000 | — | — | 5,000 | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Agentix Corp. scorecard#
Passes 1 of the 7 checks that could be worked out. Fiscal year 2025.
Valuationnot known
- –P/E below its peers' medianNo market cap.
- –Price to book below its peers' medianNo market cap.
- –Price to sales below its peers' medianNo market cap.
- –Free cash flow yield above 5%No market cap.
- –Earnings yield above the 10-year Treasury yieldNo market cap.
- –The price assumes slower growth than the last three years'No market cap.
Growth0 of 1
- –Revenue grew in the newest yearRevenue of the year before is not on file.
- –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
- –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
- ✗Earnings per share grew in the newest year-0.01 vs -0.01Diluted EPS -0.01 in fiscal 2025 against -0.01 the year before (report's currency).
- –Net income higher than five years earlierNet income of five years earlier is not on file.
- –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
Profitability0 of 2
- ✗Profitable in the newest year-$0 MNet income -$0 M in fiscal 2025.
- ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
- –Operating margin above its peers' medianNo operating margin on file.
- –Return on equity above 15%No return on equity (equity missing or negative).
- –Return on invested capital above 10%No return on invested capital on file.
- –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
Financial health0 of 3
- ✗Short-term assets cover short-term liabilities0.0×Current ratio 0.00 at the end of fiscal 2025.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- ✗Operating income covers interest five times-5.6×Operating income -5.6 times interest in fiscal 2025.
- ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
- –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
Shareholder returns1 of 1
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- ✓Share count up no more than 2% in a year0.0%Diluted shares down 0.0% in fiscal 2025.
- –Dividends and buybacks above 3% of the market valueNo market cap.
- –Free cash flow covers dividends and buybacksCash from operations or capital spending is not on file.
Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap (too old for the valuation checks, which need one at most 60 days old). A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Agentix Corp.: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD thousands; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Mar 31, 2026 | FY 2024to Mar 31, 2025 | FY 2023to Mar 31, 2024 | FY 2022to Mar 31, 2023 | FY 2021to Aug 31, 2021 | FY 2019to Aug 31, 2019 | FY 2018to Aug 31, 2018 | FY 2017to Aug 31, 2017 | FY 2016to Aug 31, 2016 | FY 2015to Aug 31, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||||
| Revenue | — | — | — | 0−100%— | 1.2—100% | — | — | 2.3−94.8%100% | 43+52.0%100% | 28—100% | |
| Cost of revenue | — | — | — | 0−100%— | 0.6—45.2% | — | — | 1.40.0%60.3% | 1.4−33.3%3.1% | 2.0—7.2% | |
| Gross profit | — | — | — | 0−100%— | 0.7—54.8% | — | — | 0.9−97.9%39.7% | 42+58.6%96.9% | 26—92.8% | |
| Research and development | 125−30.9%— | 181+3.3%— | 175−75.4%— | 712+94.9%— | 365—29446% | — | — | — | 3.7−87.0%8.6% | 28—99.8% | |
| General and administrative | 68−2.6%— | 70−79.8%— | 347+148%— | 140+111%— | 66—5356% | 4.0−54.5%— | 8.8−62.9%— | 24+2.9%1052% | 23−36.5%53.3% | 36—128% | |
| Operating expenses | 445−13.3%— | 513−31.1%— | 745−45.7%— | 1,372+2.3%— | 1,341—108148% | 121−9.7%— | 134−59.9%— | 335+0.2%14884% | 334+65.9%775% | 201—710% | |
| Operating income | −445—— | −513—— | −745—— | −1,372—— | −1,341—−108148% | −121—— | −134—— | −334—−14844% | −292r−296—−678% | −175—−617% | |
| Interest expense and finance costs | 80+87.7%— | 43+103%— | 21+1180%— | 1.6—— | — | 11−54.3%— | 25+86.1%— | 13—593% | — | — | |
| Net interest income | — | — | — | — | — | — | 25+86.1%— | 13—593% | — | — | |
| Other non-operating income (expense) | — | −54−134%— | 160r−160+7692%— | 2.0—— | −0.0—−0.4% | — | 42,655+90441%— | 47+1370%2094% | 3.2r−3.2—7.4% | — | |
| Income before tax | −486—— | −567—— | −585—— | −1,374—— | −1,340—−108093% | −133—— | −42,789—— | −381—−16938% | −296—−685% | — | |
| Income tax | 0—— | 0—— | 0—— | 0—— | 0—0.0% | — | — | — | — | — | |
| Income from continuing operations | — | — | — | — | — | — | — | — | −292—−678% | −175—−617% | |
| Net income including minority interests | — | 567−3.1%— | 585r−585—— | −1,374—— | — | — | — | — | — | — | |
| Net income attributable to shareholders | −486—— | −567—— | −585—— | −1,374—— | −1,340—−108093% | −133—— | −42,789—— | −381—−16938% | −296—−685% | −175—−617% | |
| Earnings per share, basic | — | — | — | — | -0.04—— | -6.45—— | -3,875.40r-3.88—— | -0.06—— | -0.05—— | -0.03—— | |
| Earnings per share, diluted | -0.01—— | -0.01—— | -0.01—— | — | -0.04—— | -6.45—— | -3,875.40r-3.88—— | -0.06—— | -0.05—— | -0.03—— | |
| Shares, weighted average (basic) | — | — | — | — | — | — | — | — | 6.0+1.0%— | 6.0—— | |
| Shares, weighted average (diluted) | 400.0%— | 400.0%— | 40—— | — | 35—— | 0.0+86.3%— | 0.0r11−99.8%— | 6.0−0.0%— | 6.0+1.0%— | 6.0—— | |
| Balance sheet | |||||||||||
| Cash and cash equivalents | 0.8−82.8%100% | 4.5−31.5%4.5% | 6.5−47.2%6.1% | 12+600%4.7% | 1.8—3.5% | 0.1−95.6%100% | 2.1−42.4%93.8% | 3.7+496%52.0% | 0.6−95.3%48.1% | 13—75.3% | |
| Inventory | — | — | — | — | 49—96.5% | — | — | — | — | — | |
| Other current assets | 0−100%0.0% | 96−4.0%95.5% | 100−59.9%93.9% | 249—95.3% | — | — | — | — | — | — | |
| Current assets | 0.8−99.2%100% | 100−5.7%100% | 106−59.3%100% | 261+410%100% | 51—100% | 0.1−95.6%100% | 2.1−42.4%93.8% | 3.7+496%52.0% | 0.6−95.3%48.1% | 13—75.3% | |
| Property, plant and equipment | — | — | — | — | — | 0−100%0.0% | 0.1−65.3%6.2% | 0.4−39.5%5.7% | 0.7−28.3%51.9% | 0.9—5.3% | |
| Other intangible assets | — | — | — | — | — | — | — | — | — | 3.4—19.4% | |
| Total assets | 0.8−99.2%100% | 100−5.7%100% | 106−59.3%100% | 261+410%100% | 51—100% | 0.1−95.9%100% | 2.3−68.1%100% | 7.1+451%100% | 1.3−92.7%100% | 18—100% | |
| Accounts payable | 716−26.1%92850% | 969+0.8%966% | 962−9.0%904% | 1,057+772%404% | 121—237% | 7.2—7790% | — | — | 2.8+20.7%217% | 2.3—13.2% | |
| Current liabilities | 3,596+12.2%466444% | 3,205+20.2%3196% | 2,667+6.2%2507% | 2,511+314%960% | 607—1185% | 41+324%43955% | 9.7+103%426% | 4.7+28.6%66.9% | 3.7−49.9%287% | 7.4r7.4—42.1% | |
| Non-current liabilities | 0—0.0% | 0—0.0% | 0—0.0% | 0—0.0% | 0—0.0% | 85+85.8%91398% | 46−32.2%2020% | 67—951% | — | — | |
| Total liabilities | 3,596+12.2%466444% | 3,205+20.2%3196% | 2,667+6.2%2507% | 2,511+314%960% | 607—1185% | 126+127%135353% | 55−23.2%2446% | 72+1856%1018% | 3.7—287% | — | |
| Retained earnings | −7,007—−908841% | −6,522—−6504% | −5,954—−5598% | −5,369—−2054% | −1,704—−3328% | −44,033r−44,031—−47347445% | −43,898—−1938099% | −1,109—−15637% | −728—−56557% | −432r−432—−2467% | |
| Shareholders' equity | −3,596—−466344% | −3,104—−3096% | −2,560—−2407% | −2,249—−860% | −556—−1085% | −126—−135253% | −53—−2346% | −65—−918% | −2.4−124%−187% | 10r10—57.9% | |
| Total liabilities and equity | 0.8−99.2%100% | 100−5.7%100% | 106−59.3%100% | 261+410%100% | 51—100% | 0.1−95.9%100% | 2.3−68.1%100% | 7.1+451%100% | 1.3−92.7%100% | 18—100% | |
| Shares outstanding | 400.0%— | 400.0%— | 400.0%— | 40+14.9%— | 35—— | 2.6r0.0+12306%— | 0.0r21−99.7%— | 6.00.0%— | 6.0+0.4%— | 6.0—— | |
| Cash-flow statement | |||||||||||
| Cash from operating activities | −109—— | −125—— | −110—— | −89—— | −421—−33950% | −62—— | −52—— | −76—−3396% | −13—−29.1% | −187—−659% | |
| Cash from investing activities | 0—— | 0—— | 0—— | 0—— | 0—0.0% | — | — | −9.5—−423% | — | — | |
| Debt issued | 110+10.5%— | 100−38.7%— | 163+226%— | 50—— | — | — | — | — | — | — | |
| Debt repaid | — | 0—— | −70—— | 0—— | — | — | — | — | — | — | |
| Shares issued | — | — | 0−100%— | 50−72.2%— | 180—14516% | — | — | — | — | 65—230% | |
| Cash from financing activities | 110+10.5%— | 100+7.5%— | 93−7.0%— | 100−44.4%— | 180—14516% | 60+20.0%— | 50−43.8%— | 89—3956% | — | 65—230% | |
| Exchange-rate effect on cash | −5.6−124%— | 23+98.5%— | 12+1416%— | 0.8—— | — | — | — | — | — | — | |
| Change in cash | −3.7—— | −2.1—— | −5.8−148%— | 12—— | −241—−19434% | — | −1.6−151%— | 3.1—136% | −13—−29.1% | −122—−429% | |
| Report | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Amounts in USD thousands; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the same quarter a year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | Last 12 months4 quarters to Sep 30, 2026 | Q2 FY2026to Sep 30, 2026 | Q1 FY2026to Jun 30, 2026 | Q4 FY2025to Mar 31, 2026 | Q3 FY2025to Dec 31, 2025 | Q2 FY2025to Sep 30, 2025 | Q1 FY2025to Jun 30, 2025 | Q4 FY2024to Mar 31, 2025 | Q3 FY2024to Dec 31, 2024 | Q2 FY2024to Sep 30, 2024 | Q1 FY2024to Jun 30, 2024 | Q4 FY2023to Mar 31, 2024 | Q3 FY2023to Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||||||
| Research and development | 21−91.3%— | 4.2−83.3%— | 17−83.4%— | 0*−100%— | 0−100%— | 25+112%— | 100+80.2%— | 90*+96.3%— | 23—— | 12—— | 56—— | 46*—— | −87—— | |
| General and administrative | 67−2.3%— | 170.0%— | 17−5.3%— | 17*−3.2%— | 17−0.7%— | 17−0.4%— | 18−5.8%— | 17*−17.4%— | 17−32.7%— | 17—— | 19—— | 21*—— | 25—— | |
| Operating expenses | 285−51.8%— | 68−44.6%— | 96−52.3%— | 54*−68.5%— | 67−30.3%— | 123+32.3%— | 200+32.4%— | 172*—— | 97+511%— | 93—— | 151—— | — | 16—— | |
| Operating income | −285—— | −68—— | −96—— | −54*—— | −67—— | −123—— | −200—— | −172*−780%— | −97—— | −93—— | −151—— | 25*—— | −16—— | |
| Interest expense and finance costs | 80+13.4%— | 23−4.1%— | 22+4.4%— | 21*+50.5%— | 14+22.2%— | 24+145%— | 21+178%— | 14*+87.0%— | 11+251%— | 9.8—— | 7.6—— | 7.4r7.2*—— | 3.2—— | |
| Other non-operating income (expense) | — | −23—— | −22−253%— | — | — | −21−997%— | 15+2369%— | −98*−128%— | 47—— | 2.3—— | 0.6—— | 348r28*—— | −22—— | |
| Income before tax | −364—— | −91—— | −118—— | −77*—— | −79—— | −144—— | −186—— | −182*—— | −144−2358%— | −91—— | −151—— | −3.0*—— | 6.4—— | |
| Income tax | 0—— | 0—— | 0—— | 0*—— | 0—— | 0—— | 0—— | 0*—— | 0—— | 0—— | 0—— | 0*—— | 0—— | |
| Net income including minority interests | — | — | — | — | −79*—— | −144*—— | −186—— | 952*−18.4%— | −144r−627*—— | −91r392*—— | −151—— | 1,167r−1,167*—— | −1,171r−6.4*—— | |
| Net income attributable to shareholders | −364—— | −91—— | −118—— | −77*—— | −79—— | −144—— | −186—— | −182*—— | −144−2358%— | −91—— | −151—— | −3.0*—— | 6.4—— | |
| Earnings per share, diluted | — | 0.00—— | 0.00—— | — | 0.00—— | 0.00—— | 0.00—— | — | 0.00—— | 0.00—— | 0.00—— | — | 0.00—— | |
| Shares, weighted average (basic) | — | — | — | — | — | — | — | — | 400.0%— | — | — | — | 40—— | |
| Shares, weighted average (diluted) | 400.0%— | 400.0%— | 400.0%— | — | 400.0%— | 400.0%— | 400.0%— | — | 40—— | 40—— | 40—— | — | — | |
| Balance sheet | ||||||||||||||
| Cash and cash equivalents | 1.3—100% | 1.3−76.6%100% | 0.0−99.1%100% | 0.8−82.8%100% | 6.4−22.7%100% | 5.6−11.7%100% | 4.4−51.4%100% | 4.5−31.5%4.5% | 8.3+138%5.4% | 6.3—3.7% | 9.1—5.4% | 6.5—6.1% | 3.5—3.1% | |
| Other current assets | 0—0.0% | 0—0.0% | 0—0.0% | 0−100%0.0% | 0−100%0.0% | 0−100%0.0% | 0−100%0.0% | 96−4.0%95.5% | 146+34.4%94.6% | 164—96.3% | 158—94.6% | 100—93.9% | 108—96.9% | |
| Current assets | 1.3—100% | 1.3−76.6%100% | 0.0−99.1%100% | 0.8−99.2%100% | 6.4−95.8%100% | 5.6−96.7%100% | 4.4−97.4%100% | 100−5.7%100% | 154+37.7%100% | 170—100% | 167—100% | 106—100% | 112—100% | |
| Total assets | 1.3—100% | 1.3−76.6%100% | 0.0−99.1%100% | 0.8−99.2%100% | 6.4−95.8%100% | 5.6−96.7%100% | 4.4−97.4%100% | 100−5.7%100% | 154+37.7%100% | 170—100% | 167—100% | 106—100% | 112—100% | |
| Accounts payable | 714—54452% | 714+0.4%54452% | 713+1.9%1877221% | 716−26.1%92850% | 707−33.7%11057% | 712−36.9%12706% | 700−34.6%15869% | 969+0.8%966% | 1,067−3.5%692% | 1,128—664% | 1,070—641% | 962—904% | 1,106—988% | |
| Current liabilities | 3,808—290270% | 3,808+11.2%290270% | 3,714+13.4%9773239% | 3,596+12.2%466444% | 3,504+14.1%54790% | 3,424+13.9%61125% | 3,276+13.2%74256% | 3,205+20.2%3196% | 3,071+3.8%1993% | 3,007—1769% | 2,893—1733% | 2,667—2507% | 2,958—2642% | |
| Non-current liabilities | 0—0.0% | 0—0.0% | 0—0.0% | 0—0.0% | 0—0.0% | 0—0.0% | 0—0.0% | 0—0.0% | 0—0.0% | 0—0.0% | 0—0.0% | 0—0.0% | 0—0.0% | |
| Total liabilities | 3,808—290270% | 3,808+11.2%290270% | 3,714+13.4%9773239% | 3,596+12.2%466444% | 3,504+14.1%54790% | 3,424+13.9%61125% | 3,276+13.2%74256% | 3,205+20.2%3196% | 3,071+3.8%1993% | 3,007—1769% | 2,893—1733% | 2,667—2507% | 2,958—2642% | |
| Retained earnings | −7,216—−549990% | −7,216—−549990% | −7,125—−18749574% | −7,007—−908841% | −6,930—−108350% | −6,851—−122326% | −6,707—−152025% | −6,522—−6504% | −6,340—−4114% | −6,196—−3645% | −6,105—−3657% | −5,954—−5598% | −5,951—−5316% | |
| Shareholders' equity | −3,807—−290170% | −3,807—−290170% | −3,714—−9773139% | −3,596—−466344% | −3,498—−54690% | −3,418—−61025% | −3,272—−74156% | −3,104—−3096% | −2,917—−1893% | −2,837—−1669% | −2,726—−1633% | −2,560—−2407% | −2,846—−2542% | |
| Total liabilities and equity | 1.3—100% | 1.3−76.6%100% | 0.0−99.1%100% | 0.8−99.2%100% | 6.4−95.8%100% | 5.6−96.7%100% | 4.4−97.4%100% | 100−5.7%100% | 154+37.7%100% | 170—100% | 167—100% | 106—100% | 112—100% | |
| Shares outstanding | 40—— | 400.0%— | 400.0%— | 400.0%— | 400.0%— | 400.0%— | 400.0%— | 400.0%— | 400.0%— | 40—— | 40—— | 40—— | 40—— | |
| Cash-flow statement | ||||||||||||||
| Cash from operating activities | −23—— | −3.5*−217%— | −26—— | 15*—— | −7.9*—— | 3.0*−59.3%— | −118—— | −43*—— | −87*—— | 7.4*—— | −2.4—— | −66*—— | −37*—— | |
| Cash from investing activities | 0—— | 0*—— | 0—— | 0*—— | 0*—— | 0*—— | 0—— | 0*—— | 0*—— | 0*—— | 0—— | 0*—— | 0*—— | |
| Debt issued | 43−74.6%— | 7.0*+1900%— | 26−73.8%— | 0*−100%— | 10*−59.6%— | 0.4*−96.5%— | 100+400%— | 45*+4.7%— | 25*−50.0%— | 10*—— | 20—— | 43*—— | 50*—— | |
| Debt repaid | — | — | — | — | — | — | — | 0*—— | 0*—— | — | — | 0*—— | 0*—— | |
| Shares issued | — | — | — | — | — | — | — | — | — | — | — | 0*—— | 0*—— | |
| Cash from financing activities | 43−74.6%— | 7.0*+1900%— | 26−73.8%— | 0*−100%— | 10*−59.6%— | 0.4*−96.5%— | 100+400%— | 45*+4.7%— | 25*−50.0%— | 10*—— | 20—— | 43*—— | 50*—— | |
| Exchange-rate effect on cash | −25−133%— | −2.2*—— | −0.6−103%— | −20*—— | −1.4*−102%— | −2.2*—— | 18—— | −5.7*—— | 64*—— | −20*—— | −15—— | — | — | |
| Change in cash | −4.3—— | 1.3*+7.1%— | −0.7—— | −5.6*—— | 0.8*−58.8%— | 1.2*—— | −0.1−103%— | −3.8*−224%— | 1.9*—— | −2.7*—— | 2.5—— | 3.1*—— | −24*—— | |
| Report | Worked out | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | |
* Worked out from reported figures: a quarter the company states only within a year-to-date figure (cash flows are reported that way), or the fourth quarter as the fiscal year minus the first nine months.
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
Events at Agentix Corp.#
What the company reported to the SEC within four business days (Form 8-K), newest first.
No warning signs in the last three years: no bankruptcy, delisting notice, withdrawn financial statements, auditor change, cybersecurity incident, debt called early or impairment was reported.
Acquisition or sale completed 2 · Directors and officers 3 · Material agreement 2
Source: SEC EDGAR, Form 8-K item numbers · as of Jun 14, 2022
Peer comparison · Biotechnology
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Agentix Corp.🇺🇸 | $31 M | — | — | — |
| Novo Nordisk A/S🇩🇰 | $203.2 B | 13.1× | 33.1% | +10.8% |
| Vertex Pharmaceuticals Incorporated🇺🇸 | $134.3 B | 33.8× | 30.7% | +8.9% |
| Moderna, Inc.🇺🇸 | $90.1 B | — | -110.5% | -39.9% |
| Regeneron Pharmaceuticals, Inc.🇺🇸 | $84.1 B | 17.5× | 28.5% | +1.0% |
| Argenx SE🇳🇱 | $52.8 B | 40.9× | 31.1% | +89.9% |
| CSL Limited🇦🇺 | $51.6 B | — | -16.4% | — |
| Samsung Biologics Co., Ltd.🇰🇷 | $51.5 B | 40.5× | 39.2% | — |
| UCB SA🇧🇪 | $48.6 B | 26.3× | 20.1% | +31.1% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Novo Nordisk A/S$203.2 B
- Vertex Pharmaceuticals Incorporated$134.3 B
- Moderna, Inc.$90.1 B
- Regeneron Pharmaceuticals, Inc.$84.1 B
- Argenx SE$52.8 B
- CSL Limited$51.6 B
Sources and freshness
- Market cap:
- Jan 7, 2022 (last known)
- Annual results:
- For year ending March-2026
- Balance sheet:
- As of March-2026
- Profile updated:
- Nov 16, 2026
Figures from SEC filing, value.today research, SEC annual report; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Agentix Corp.? Verify and update this profile — free
Show Agentix Corp.'s ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.